Treatment with carfilzomib/AGI-6780 led to increased death of primary CD138+ cells from MM patients and exhibited a favorable cytotoxicity profile towards peripheral blood mononuclear cells and bone marrow-derived stromal cells. The gene discussed is SDC1; the disease is Miyoshi myopathy.